VOLV.A

297.8

+0.13%↑

ASSA.B

329.5

-0.18%↓

SAAB.B

632.7

-0.92%↓

SEB.A

177.95

-0.03%↓

SKA.B

244.4

0%↓

VOLV.A

297.8

+0.13%↑

ASSA.B

329.5

-0.18%↓

SAAB.B

632.7

-0.92%↓

SEB.A

177.95

-0.03%↓

SKA.B

244.4

0%↓

VOLV.A

297.8

+0.13%↑

ASSA.B

329.5

-0.18%↓

SAAB.B

632.7

-0.92%↓

SEB.A

177.95

-0.03%↓

SKA.B

244.4

0%↓

VOLV.A

297.8

+0.13%↑

ASSA.B

329.5

-0.18%↓

SAAB.B

632.7

-0.92%↓

SEB.A

177.95

-0.03%↓

SKA.B

244.4

0%↓

VOLV.A

297.8

+0.13%↑

ASSA.B

329.5

-0.18%↓

SAAB.B

632.7

-0.92%↓

SEB.A

177.95

-0.03%↓

SKA.B

244.4

0%↓

Search

LIFCO AB-B SHS

Закрыт

276.8 -0.22

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

273.6

Макс.

278.2

Ключевые показатели

By Trading Economics

Доход

524M

1.4B

Продажи

692M

7.5B

P/E

Средняя по отрасли

36.38

61.065

Прибыль на акцию

2.29

Дивидендная доходность

0.93

Рентабельность продаж

18.795

Сотрудники

7,814

EBITDA

211M

1.9B

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.93%

2.23%

Следующий отчет о доходах

30 мар. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-11B

132B

Предыдущая цена открытия

277.02

Предыдущая цена закрытия

276.8

LIFCO AB-B SHS График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 мар. 2026 г., 23:47 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 мар. 2026 г., 22:55 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 мар. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

23 мар. 2026 г., 23:59 UTC

Обсуждения рынка

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 мар. 2026 г., 23:50 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 мар. 2026 г., 23:37 UTC

Обсуждения рынка

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Global Equities Roundup: Market Talk

23 мар. 2026 г., 22:42 UTC

Обсуждения рынка
Главные новостные события

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 мар. 2026 г., 22:40 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 мар. 2026 г., 22:23 UTC

Обсуждения рынка

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 мар. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 мар. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 мар. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 мар. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 мар. 2026 г., 22:18 UTC

Приобретения, слияния, поглощения

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 мар. 2026 г., 22:15 UTC

Приобретения, слияния, поглощения

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 мар. 2026 г., 22:08 UTC

Обсуждения рынка

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

23 мар. 2026 г., 21:42 UTC

Обсуждения рынка

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 мар. 2026 г., 21:32 UTC

Отчет

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 мар. 2026 г., 21:10 UTC

Главные новостные события

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

23 мар. 2026 г., 20:50 UTC

Обсуждения рынка
Отчет
Главные новостные события

Basic Materials Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

LIFCO AB-B SHS Прогноз

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании LIFCO AB-B SHS

Lifco AB (publ) engages in the dental, demolition and tools, and systems solutions businesses in Sweden, Norway, Germany, rest of Europe, the United Kingdom, Asia, Australia, Italy, North America, and internationally. It is involved in the distribution of dental equipment, such as denture attachments, disinfectants, saliva ejectors, bite registration and dental impression materials, bonding agents, and other consumables, as well as develops and sells medical record systems. The company also operates dental laboratory. In addition, it develops, manufactures, and sells demolition robots, forest machines, and crane and excavator attachments to heavy machine manufacturing, infrastructure, demolition, construction, forestry, nuclear, cement, and process industries. Further, the company offers machinery and equipment for electrical installations and electricity production, electrical equipment, equipment for recycling of various materials, compressors for ships and offshore installations, interiors for service vehicles, and trailers for vehicle transports. The company was founded in 1993 and is based in Enköping, Sweden. Lifco AB (publ) is a subsidiary of Carl Bennet AB.
help-icon Live chat